siRNA, miRNA and their possible roles in molecular therapy of chronic human hepatitis b virus infection and hepatocellular carcinoma

siRNA, miRNA AND THEIR POSSIBLE ROLES IN MOLECULAR THERAPY OF CHRONIC HUMAN HEPATITIS B VIRUS INFECTION AND HEPATOCELLULAR CARCINOMA LI YANG (M.Sc ShanDong University, People’s Republic of China) A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT OF BIOCHEMISTRY NATIONAL UNIVERSITY OF SINGAPORE 2007 I ACKNOWLEDGEMENTS This dissertation is dedicated to my family My parents and my brothers have always been encouraging and supporting me no matter how far we are separated They are the source of my intelligence and power I wish to express sincere gratitude to my supervisor Dr Theresa Tan for her serious, responsible supervision on my project all the way during the course of my candidature Her scientific attitude towards research and professionalism has impressed me and will benefit me lifelong I deeply thank my co-supervisors Dr Shanthi Wasser and A/P Lim Seng Gee Their valuable suggestions and continuous support mean a lot to me I thank all the past and current members in our laboratory including: Sherry Neo, Geraldine Yeo, Wu Juan, Yang Fei, Yang Shu, Bai Jing, Bian HaoSheng, Ho Sok Ying, Thomas Neo, Tan WeiQi for their help during the whole course of my study I thank all our collaborators in the National University Hospital I would like to thank Doctor Aung for preparing RNA samples from surgical tissues, Ms Regina Chan for providing technical support for the real-time PCR assays and graduate student Wei Chun for his help in primary hepatocytes culture I would like to thank all my friends who shared the four fruitful years with me: Zhang gang, Li JianHui, Wu BinHui, Hou AiHua, Meng Lei, Dr Zhang Yong, Zhang ShaoChong, Wang PengHua, Ho ZiZhong, Fei WeiHua, Dr Hu ChuangJiong, Ho ZiZhong, Wang Han, WeiWen, Yang Meng, Ding Ying, Song GuangHui, Li Guang, Pradeep, my dear sisters Wang JunZhu, Song Ran, Ding Hui, and lot more Your friendship is one of the most precious things in my life Last but not the least, I would like to thank National University of Singapore for giving me the opportunity for pursuing a higher degree and generously offering me research scholarship II PUBLICATIONS The major part of this work has been published in: Genome-wide expression profiling of RNA interference of hepatitis B virus gene expression and replication Y Li, S Wasser, S.G Lim and T.M.C Tan Cell Mol Life Sci 2004 Aug; 61(16):2113-2124 MicroRNA Expression Profiling in Human Liver Tumors Y Li, WQ Tan, T Neo, MO Aung , S Wasser, S.G Lim and T.M.C Tan Awarded with the Young scientist Award and published in 20th IUBMB International Congress f Biochemistry and Molecular Biology and 11th FAOBMB Congress Abstracts 2006, Kyoto, Japan Page:145 Other publications as co-author: Synthesis and the biological evaluation of 2-benzenesulfonylmethyl-5- substituted -sulfanyl-[1,3,4]-oxadiazoles as potential anti-Hepatitis B virus agents Theresa May Chin Tan, Yu Chen, Kah Hoe Kong, Jing Bai, Yang Li, Seng Gee Lim, Thiam Hong Ang, Yulin Lam Antiviral Res, 2006, 71, 7-14 Manuscripts in preparation: Deregulation of the miR-106b-25 cluster in Human Hepatocellular Carcinoma Y Li, WQ Tan, T Neo, MO Aung , S Wasser, S.G Lim and T.M.C Tan 2007 III SMALL RNA MOLECULES AS POTENTIAL DIAGNOSTIC AND THERAPEUTIC TOOL FOR HEPATIC DISEASES TABLE OF CONTENTS Chapter I: Introduction 1.1 HCC……………………………………………………………………………… 1.1.1 Epidemiology of Hepatocellular Carcinoma…………………………………… 1.1.2 Risk Factors of HCC………………………………………………….……….… 1.1.3 Diagnoses of HCC 1.1.4 Current Treatments of HCC…………………………………………… 1.2 HBV-the Virus and the Disease…………………………………………… 8 10 12 14 14 14 16 16 17 17 19 19 22 24 24 26 30 30 31 32 35 1.2.1 HBV: the Virus…………………………………………………………………… 1.2.1.1 The structure of HBV particles……………………………………………… 1.2.1.2 The HBV genome ………………………………… 1.2.1.3 Life cycle of HBV ………………………………………………….…… 1.2.2 Hepatitis B: the Disease………………………………………………………… 1.2.2.1 Prevalence………………………………………………………….…………… 1.2.2.2 Clinical diagnosis and prevision………………… 1.2.2.3 Therapeutic treatment of hepatitis B…………………………………………… 1.2.2.3.1 Interferon-α…………………………………… 1.2.2.3.2 Nucleoside analogues………………………… 1.2.2.3.3 Sequence-specific approaches… 1.3 RNAi……………………………………………………………………………… 1.3.1 The Mechanism of RNA Interference ……………………….…………… 1.3.2 History of RNAi Study ……………………………………………………… 1.3.3 RNAi and Applications…………………………………………….……… …… 1.3.3.1 RNAi as a tool for functional genomics…………………………………… 1.3.3.2 RNAi as gene-specific therapeutics…………………………………….……… 1.3.3.3 Challenges for the applications of RNAi………………………………………… 1.3.3.3.1 Design of siRNA……………………………………………………………… 1.3.3.3.2 Delivery…………………………………………………………………… 1.3.3.3.3 Specificity of RNAi……………………………………………………….… 1.4 MicroRNA……………………………………………………………………… 1.4.1Biogenesis of miRNA and Mechanisms of miRNA-mediated Gene Regulation…………………………………………………… 35 1.4.2 History of miRNA Study………………………………………………………… 41 IV 1.4.3 Identification of miRNA Genes……………………………………………… 1.4.4 Prediction of miRNA Targets…………………………………………… 1.4.5 miRNAs and Human Cancers …………… 1.4.6 miRNAs deregulated in HCC……………………………………………… … 42 45 46 49 Chapter II Objectives and Significance 2.1 The RNAi Approach for Inhibition of Hepatitis B Viral Gene Expression……………………………………… 52 2.2 miRNAs and HCC……………………………………………………………… 54 Chapter III Materials and Methods 3.1 Materials………………………………………………………………………… 3.1.1 Cell Cultures…………………………………………………………………… 3.1.1.1 Human tumor cell lines………………………………………… …………… 3.1.1.2 Primary hepatocytes………………………………………………………….… 3.1.2 Surgical Tissue Specimens (tumor vs non-tumor)………….………………… 3.1.3 Preparation of Media for Cell Culture…………… ……………………… … 3.1.4 Oligos, Reagents and Special Chemicals……………………………………… 3.2 Methods…………………………………………………………………………… 3.2.1 Inhibition of HBV Gene Expression by siRNAs………………………… …… 3.2.1.1 Cell culture………………………………………………………….………… 3.2.1.2 Synthesis of siRNA…………………………………………………………… 3.2.1.3 Transfection with siRNAs……………………………………………………… 3.2.1.4 Estimation of transfection efficiency…………………………………………… 3.2.1.5 Cell viability assay………………………………………………………….… 3.2.1.6 Quantitative assay of HBsAg…………………………………………………… 3.2.1.7 HBV viral DNA quantification……………………………… ……… 3.2.1.8 RNA extraction using RNezsy mini kit and quantification………………… 3.2.1.9 RNA extraction using TRIzol and quantification……………………………… 3.2.1.10 Denaturing agarose gel electrophoresis of RNA…………………………… 3.2.1.11 Reverse Transcription and PCR…….………………………………………… 3.2.1.12 Microarray procedures and data analysis……………………………… 3.2.2 Analysis of miRNA Expression and Function in HCC………………… 3.2.2.1 Cell culture…………………………………………………….… …… 3.2.2.2 RNA extraction and quantification……………………………… 3.2.2.3 Mature miRNA expression profiling………………………………… … 3.2.2.4 TaqMan® microRNA individual assay………………… .…………… 3.2.2.5 Quantification of miRNA precursors…………………………………………… V 57 57 57 57 57 57 58 59 59 59 59 60 62 62 62 63 65 65 66 67 69 70 70 71 71 74 74 3.2.2.6 Transfection of cell lines with miRNA inhibitors……………………….……… 76 3.2.2.7 Cell viability assay…………………………………………………….….…… 77 3.2.2.8 Soft agar assay for colony formation…………………………….…………… 77 Chapter IV Inhibition of HBV Gene Expression by siRNAs 4.1 Introduction…………………………………………………………….… …… 81 4.2 Selection and Transfection of HBV Specific siRNAs………………… 82 4.2.1 Selection of HBV Specific siRNAs……………………… ……………….…… 82 4.2.2 Selection of Transfection Reagents……………………… ………………….… 83 4.2.3 Transfection Efficiency of HBV Specific siRNA…………………………….… 86 4.3 Inhibition of HBsAg Expression and Reduction in Virion Production……………….…………………….…… 87 4.3.1 Concentration Dependent Inhibition of HBsAg Expression…………… …… 4.3.2 Effect of siRNA on HBsAg Transcripts in PLC/PRF/5 and 2.2.15 Cells……… 4.3.3 Effect of siRNA on HBV Transcripts in 2.2.15 Cells…………………… …… 4.3.4 Effect of siRNA on Virion Production in 2.2.15 Cells……………….….……… 4.3.5 The Time Course of HBsAg Inhibition by siRNA………………………… 4.3.6 Reversal of RNAi………………………………………………………… …… 87 90 92 93 94 96 4.4 Specificity of the Effects of siRNA…………………… ………………… 97 4.4.1 Effects of siRNA on Cell Viability………………………………… …………… 97 4.4.2 Expression Profiling……………………………………………….…………… 98 4.5 Discussion…………………… …………………… …………………… …… 103 4.5.1 Inhibition of HBV Gene Expression by siRNAs……………………………… 103 4.5.2 Microarray Analysis of HBV-induced Changes in Gene Expression………… 105 4.5.3 Specificity of the Effects of siRNAs……………………………………………… 106 4.5.4 Comparison of Studies on siRNA’s effect on HBV…………………………… 108 4.6 Conclusion…………………… …………………… …………………… … 113 Chapter V microRNA and HCC 5.1 Introduction……………………………………………………………… …… 5.2 miRNA Expression in Livers ……… ……… ……… ……… 115 116 5.2.1 Choice of Patient Samples and Validation of RT-real-time PCR Approach… 117 5.2.1.1 Selection of patient RNA samples……………………….….…… 117 5.2.1.2 Quality of RNA preparations………………………………………… ……… 118 5.2.1.3 Validation of RT-real-time PCR approach to quantify the expression of pri- and pre-miRNAs ……………………………………………… 119 5.2.2 Deregulation of miRNA Expressions in HCC………………………………… 122 VI 5.2.2.1 Mature miRNA expression profile……………………………………….…… 5.2.2.1.1 Identification of miRNAs that are deregulated in HCC ……….……… 5.2.2.1.2 miRNA expression in cirrhotic liver samples …………………….….……… 5.2.2.2 Confirmation of the deregulation of miRNAs in 56 paired HCC samples….…… 5.2.2.3 Upregulation of the expression of the miRNA-106b-25 cluster in HCC……… 5.2.2.4 Upregulation of the expression of the miRNA-106b-25 cluster in HCC cell lines 5.3 Functions of Deregulated miRNAs ……… .……… .……… 5.3.1 Effects of the Deregulated miRNAs on Cell Growth…………………………… 5.3.2 Effect of the miR-106b-25 Cluster on Cell Growth……………….…………… 5.3.3 Effect of the miR-106b-25 Cluster on Anchorage-independent Growth………………………………………… ………… 5.3.4 Effect of the Deregulated miRNAs on Anchorage-independent Growth………………………………………… ………… 122 124 125 126 129 130 133 133 135 137 138 5.4 Prediction of the Putative Targets of the miR-106b-25 Cluster…… 140 5.5 Discussion ……… ……… ……… ……… ……… ……… 141 5.5.1 Deregulation of miRNAs in HCC……………………………………… ……… 5.5.2 Validation of the Deregulation of miRNAs in HCC……………….…………… 5.5.3 The miRNA-106b-25 Cluster as an Oncogenic Cluster……………………… 5.6 Conclusion………………… ………………… ………………… …………… 142 146 147 150 Chapter VI Conclusion 6.1 Summary of Important Findings………………………………………… …… 6.2 Suggestions for Future Work………………………………………….… ….…… 153 1555 REFERENCES………………………………………………………………………… 158 SUPPLEMENTARY MATERIALS………………………………………………… 181 VII SUMMARY The study aims mainly to investigate the therapeutic and diagnostic potential of small RNA molecules in hepatic diseases The focus is on hepatitis B infection and hepatocellular carcinoma (HCC) HCC is a major health problem worldwide and chronic infection with hepatitis B virus (HBV) is a major risk factor for HCC This study can be divided into two parts The first part of this study was aimed at investigating the use of the RNA interference (RNAi) approach for inhibition of HBV gene expression while the next was aimed at evaluating the role of microRNAs (miRNAs) in human HCC In the first part of this study, small interfering RNAs (siRNAs) that target HBsAg transcripts were designed and the effects of these siRNAs on the HBsAg producing cell line, PLC/PRF/5 and the HBV producing cell line, 2.2.15 were studied We showed that siRNAs specific for two conserved regions within the HBsAg gene can inhibit the antigen production in the two human liver cell lines which constitutively produce and secrete HBsAg The inhibitory effect was concentration-dependent for the PLC/PRF/5 cells as well as the 2.2.15 cells Decreases in the corresponding viral transcript levels were observed The inhibitory effect was observed within 24 hours and was still evident days after the initial treatment with siRNAs Significant reduction in virion production was also observed for the 2.2.15 cells To address the question on the specificity of the siRNA-mediated inhibition, we first examined the effects on cell growth and viability This was not affected in both cell lines cDNA microarrays were also used to examine genome-wide changes in gene regulation No significant off-target gene regulation was observed in both cell lines Our data also showed that unlike the general interferon VIII response to long dsRNA molecules, there is no single siRNA-induced response to siRNA duplexes in mammalian cells Our findings thus indicate that siRNA can be specific in mediating down-regulation of viral gene expression leading to reduction in virion production In the second part of the study, miRNA expression profiling using reverse transcription (RT)-real-time PCR was carried out in 10 paired HCC tumor and non-tumor samples The expression profiles showed that of the 157 miRNAs examined, 28 were upregulated while 14 were downregulated The deregulation of some of the most frequently upregulated miRNAs (miR-15b, miR-25, miR-93, miR-106b, miR-135a, miR-182 miR-221, miR-222 and miR-224) was confirmed in 56 paired HCC clinical samples and in HCC cell lines It is of interest to note that members of the miR-17-92 cluster and its homology, the miR-106b-25 cluster were among those that were upregulated To date, the miR-17-92 cluster is one of the best characterized miRNAs and is implicated in the tumorgenesis of several types of human cancers including B-cell lymphoma, breast cancer, colon cancer, lung cancer and pancreatic cancer Our data from the knock-down studies in cell lines for the miR-106b-125 cluster showed that the expression of the cluster is necessary for cell proliferation and for the anchorage-independent growth Taken together, these data indicates that the miR-106b-25 cluster, like its homology, the miR-17-92 cluster, may also have oncogenic properties In conclusion, siRNAs can be used as an efficient tool to inhibit HBV gene expression and viral replication in vitro It is possible to design siRNAs which have little off-target effects, IX although care should always be taken to verify that this is indeed so In addition, our study on miRNAs in HCC indicates that miRNAs are deregulated in HCC, and the miRNA-106b-25 cluster together with some of the most frequently upregulated miRNAs in HCC may function as oncogenic genes Our data also indicates that miRNA profiling might aid in cancer diagnosis and understanding of miRNA function in cancers may provide therapeutic targets Keywords: Short interfering RNA, microRNA, hepatocellular carcinoma, hepatitis B, expression profiling, cDNA microarray X Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, Jacob ST, Ghoshal K 2006 Downregulation of miR-122 in the rodent and human hepatocellular carcinomas J Cell Biochem 99(3):671-678 Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T 2001 Identification of novel genes coding for small expressed RNAs Science 294(5543):853-858 Lai EC, Tomancak P, Williams RW, Rubin GM 2003 Computational identification of Drosophila microRNA genes Genome Biol 4(7): R42 Lau NC, Lim LP, Weinstein EG, Bartel DP 2001 An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans Science 294(5543), 858–862 le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, Mercatelli N, Ciafre SA, Farace MG, Agami R 2007 Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation EMBO J 2007 Lee RC, Feinbaum RL, Ambros V 1993 The C elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 Cell 75(50): 843-854 Lee SB, Esteban M 1994 The interferon-induced double-stranded RNA-activated protein kinase induces apoptosis Virology 199(2):491-496 Lee RC, Ambros V 2001 An extensive class of small RNAs in Caenorhabditis elegans Science 294(5543), 862–864 Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A, Salvaterra P, Rossi J 2002 Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells Nat Biotechnol 20(5):500-505 Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN 2003 The nuclear RNaseIII Drosha initiates microRNA processing Nature 425(6956): 415–419 Lee RC, Feinbaum R, Ambros V 2004a A short history of a short RNA Cell 116(2 Suppl): S89-92 Lee YS, Nakahara K, Pham JW, Kim K, He Z, Sontheimer EJ, Carthew RW 2004b Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways Cell 117(1):69-81 Lee JW, Kim MR, Soung YH, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH 2006 Mutational analysis of the CASP6 gene in colorectal and gastric carcinomas APMIS 114(9):646-650 168 Legendre M, Lambert A, Gautheret D 2005 Profile-based detection of microRNA precursors in animal genomes Bioinformatics 21(7): 841-845 Lengyel P 1982 Biochemistry of interferons and their actions Annu Rev Biochem 51:251-285 Leung AK, Calabrese JM, Sharp PA 2006 Quantitative analysis of Argonaute protein reveals microRNA-dependent localization to stress granules Proc Natl Acad Sci U S A 103(48):18125-18130 Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB 2003 Prediction of mammalian microRNA targets Cell 115(7):787-798 Li Y, Wasser S, Lim SG and Tan TMC 2004 Genome-wide expression profiling of RNA interference of hepatitis B virus gene expression and replication Cell Mol Life Sci 61(16):2113-2124 Lim LP, Glasner ME, Yekta S, Burge CB, Bartel DP 2003a Vertebrate microRNA genes Science 299(5612): 1540 Lim LP, Lau NC, Weinstein EG, Abdelhakim A, Yekta S, Rhoades MW, Burge CB, Bartel DP 2003b The microRNAs of Caenorhabditis elegans Genes Dev 17(8): 991-1008 Lin SY, Johnson SM, Abraham M, Vella MC, Pasquinelli A, Gamberi C, Gottlieb E, Slack FJ 2003 The C elegans hunchback homolog, hbl-1, controls temporal patterning and is a probable microRNA target Dev Cell 4(5):639-650 Lin KW, Kirchner JT 2004 Hepatitis B Am Fam Physician 69 (1): 75-82 Lingel A, Simon B, Izaurralde E, Sattler M 2003 Structure and nucleic-acid binding of the Drosophila Argonaute PAZ domain Nature 426(6965):465-469 Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C,Ferracin M, Dumitru CD, Shimizu M, Zupo S, Dono M et al 2004a An oligonucleotide microchip for genomewide microRNA profiling in human and mouse tissues Proc Natl Acad Sci U S A 101(26): 9740-9744 Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L, Hannon GJ 2004b Argonaute2 is the catalytic engine of mammalian RNAi Science 305(5689):1437-1441 Liu J, Guo Y, Xue CF, Li YH, Huang YX, Ding J, Gong WD, Zhao Y 2004c Effect of vector-expressed siRNA on HBV replication in hepatoblastoma cells World J Gastroenterol.10(13):1898-1901 169 Liu J, Rivas FV, Wohlschlegel J, Yates JR 3rd, Parker R, Hannon GJ 2005a A role for the P-body component GW182 in microRNA function Nat Cell Biol 7(12): 1261-1266 Liu SA, Wei HS, Dong QM, Guo JJ, Qin J, Zhang QY, Liu ZY, Yan J, Cheng J 2005b Inhibition of HBsAg and HBeAg secretion by RNA interference of the polymerase gene sequence of hepatitis B virus: an experimental study Zhonghua Yi Xue Za Zhi 85(43):3079-3083 Livak KJ, Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) method Methods 25(4): 402-408 Llovet JM, Burroughs A, Bruix J 2003 Hepatocellular carcinoma Lancet 362(9399):1907-1917 Loeb KR, Jerome KR, Goddard J, Huang M, Cent A, Corey L 2000 High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system Hepatology 32(3): 626-629 Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U 2004 Nuclear export of microRNA precursors Science 303(5654): 95–98 Ma DZ, Xu Z, Liang YL, Su JM, Li ZX, Zhang W, Wang LY, Zha XL 2005a Down-regulation of PTEN expression due to loss of promoter activity in human hepatocellular carcinoma cell lines World J Gastroenterol 11(29):4472-4477 Ma JB, Yuan YR, Meister G, Pei Y, Tuschl T, Patel DJ 2005b Structural basis for 5'-end-specific recognition of guide RNA by the A fulgidus Piwi protein Nature 434(7033):666-670 MacCallum FO 1947 Homologous Serum Jaundice Lancet 2: 691-692 Macrae IJ, Zhou K, Li F, Repic A, Brooks AN, Cande WZ, Adams PD, Doudna JA 2006 Structural basis for double-stranded RNA processing by Dicer Science 311(5758): 195–198 Mahoney FJ, Kane M 1999 Hepatitis B vaccine In: Plotkin SA and Orenstein WA, eds Vaccines, 3rd ed Philadelphia, W.B Saunders Company: 158-182 Martin MM, Lee EJ, Buckenberger JA, Schmittgen TD, Elton TS 2006 Microrna-155 regulates human angiotensin II type receptor expression in fibroblasts J Biol Chem 281(27):18277–18284 Martinez MA, Gutierrez A, Armand-Ugon M, Blanco J, Parera M, Gomez J, Clotet B, Este JA 2002 Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication AIDS 16(18):2385-2390 170 McCaffrey AP, Meuse L, Karimi M, Contag CH, Kay MA 2003a A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice Hepatology 38(2):503-508 McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, Wieland SF, Marion PL, Kay MA 2003b Inhibition of hepatitis B virus in mice by RNA interference Nat Biotechnol 21(6):639-644 McGlynn KA, London WT 2005 Epidemiology and natural history of hepatocellular carcinoma Best Pract Res Clin Gastroenterol 19(1):3-23 McManus MT, Sharp PA 2002 Gene silencing in mammals by small interfering RNAs Nat Rev Genet 3(10):737-747 Meister G, Landthaler M, Dorsett Y, Tuschl T 2004 Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing RNA 10(3):544-550 Meyer T, Kneissel M, Mariani J, Fournier B 2000 In vitro and in vivo evidence for orphan nuclear receptor RORalpha function in bone metabolism Proc Natl Acad Sci U S A 97(16): 9197-9202 Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP, James RJ 2003 Reduced accumulation of specific microRNAs in colorectal neoplasia Mol Cancer Res 1(12): 882–891 Mohr L, Geissler M, Blum HE 2002 Gene therapy for malignant liver disease Expert Opin Biol Ther 2(2):163-175 Moore MD, McGarvey MJ, Russell RA, Cullen BR, McClure MO 2005 Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors J Gene Med 7(7):918-925 Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B, McSwiggen JA, Vargeese C, Bowman K, Shaffer CS, Polisky BA, Zinnen S 2005a Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication Hepatology 41(6): 1349–1356 Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B 2005b Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs Nat Biotechnol 23(8):1002-10007 171 Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K 2006 Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues Oncogene 25(17):2537-2545 Napoli C, Lemieux C, Jorgensen R 1990 Introduction of a chalcone synthase gene into Petunia results in reversible co-suppression of homologous genes in trans Plant Cell 2(4): 279-289 Ng IO, Ng MM, Lai EC, Fan ST 1995 Better survival in female patients with hepatocellular carcinoma Possible causes from a pathologic approach Cancer 75(1):18-22 Ng KK, Poon RT 2005 Radiofrequency ablation for malignant liver tumor Surg Oncol 14 (1): 41-52 Nishikura K 2001 A short primer on RNAi: RNA-directed RNA polymerase acts as a key catalyst Cell 107(4):415-418 Norton PA, Gong Q, Mehta AS, Lu X, Block TM 2003 Hepatitis B virus-mediated changes of apolipoprotein mRNA abudance in cultured hepatoma cells J Virol 77(9): 5503-5506 Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman J, Shankar P, Sharp PA 2002 siRNA-directed inhibition of HIV-1 infection Nat Med 8(7):681-686 Nykanen A, Haley B, Zamore PD 2001 ATP requirements and small interfering RNA structure in the RNA interference pathway Cell 107(3): 309-321 O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT 2005 c-Myc-regulated microRNAs modulate E2F1 expression Nature 435(7043):839-843 Okamura K, Ishizuka A, Siomi H, Siomi MC 2004 Distinct roles for Argonaute proteins in small RNA-directed RNA cleavage pathways Genes Dev 18(14): 1655-1666 Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, Yoshida Y, Seto M 2004 Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma Cancer Res 64(9): 3087–3095 Otsuka M, Aizaki H, Kato N, Suzuki T, Miyamura T, Omata M, Seki N 2003 Differential cellular gene expression induced by hepatitis B and C viruses Biochem Biophys Res Comm 300(2): 443-447 Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, Chiappetta G, Liu CG, Santoro M, Negrini M, Croce CM, Fusco A 2006 MicroRNA deregulation in human thyroid papillary carcinomas Endocr Relat Cancer 13(2):497-508 172 Pan XC, Chen Z, Ni Q, Yang ZG, Xu N, Jin HY 2006 Application of PCR-based tRNAval Pol III-shRNA expression cassettes in screening of efficient siRNA for inhibiting hepatitis B virus Zhejiang Da Xue Xue Bao Yi Xue Ban 35(2):154-160 Park WS, Miyano-Kurosaki N, Hayafune M, Nakajima E, Matsuzaki T, Shimada F, Takaku H 2002 Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference Nucleic Acids Res 30(22): 4830-4835 Parkin DM, Pisani P, Munoz N, Ferlay J 1999 The Global Health Burden of Infection Associated Cancer, in Weiss RA, Beral V, Newton R (eds) Infections and Human Cancer Cancer Surveys.33: 5–33 Parkin DM, Bray F, Ferlay J, Pisani P 2001 Estimating the world cancer burden: Globocan 2000 Int J Cancer 94(2):153-156 Parkin DM, Bray F, Ferlay J, Pisani P 2005 Global cancer statistics, 2002 CA Cancer J Clin 55(2):74-108 Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM 2006 Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.Cancer Res 66(24):11590-11593 Peng J, Zhao Y, Mai J, Pang WK, Wei X, Zhang P, Xu Y 2005 Inhibition of hepatitis B virus replication by various RNAi constructs and their pharmacodynamic properties J Gen Virol 86(Pt 12):3227-3234 Persengiev SP, Zhu X, Green MR 2004 Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs) RNA 10(1):12-18 Pfeffer S, Sewer A, Lagos-Quintana M, Sheridan R, Sander C, Grasser FA, van Dyk LF, Ho CK, Shuman S, Chien M, Russo JJ, Ju J, Randall G, Lindenbach BD, Rice CM, Simon V, Ho DD, Zavolan M, Tuschl T 2005 Identification of microRNAs of the herpesvirus family Nat Methods 2(4): 269-276 Poon RT, Fan ST 2004 Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome Liver Transpl 10 (2 Suppl 1): S39-S45 Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, Pfeffer S, Tuschl T, Rajewsky N, Rorsman P, Stoffel M 2004 A pancreatic islet-specific microRNA regulates insulin secretion Nature 432(7014):226-230 173 Provost P, Dishart D, Doucet J, Frendewey D, Samuelsson B, Radmark O 2002 Ribonuclease activity and RNA binding of recombinant human Dicer EMBO J 21(21): 5864–5874 Qi Y, Denli AM, Hannon GJ 2005 Biochemical specialization within Arabidopsis RNA silencing pathways Mol Cell 19(3):421-428 Randall G, Grakoui A, Rice CM 2003 Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs Proc Natl Acad Sci U S A 100(1):235-240 Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G 2000 The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans Nature 403(6772):901-906 Ren GL, Bai XF, Zhang Y, Chen HM, Huang CX, Wang PZ, Li GY, Zhang Y, Lian JQ 2005 Stable inhibition of hepatitis B virus expression and replication by expressed siRNA.Biochem Biophys Res Commun 335(4):1051-1059 Ren JL, Pan JS, Cheng T, Dong J, Lu YP, Huang SJ, Shi HX, Wang L, Lian YM 2006a RNA interference inhibits hepatitis B virus gene expression and replication in HepG2-N10 cells.Chin J Dig Dis 7(4):230-236 Ren X, Luo G, Xie Z, Zhou L, Kong X, Xu A 2006b Inhibition of multiple gene expression and virus replication of HBV by stable RNA interference in 2.2.15 cells J Hepatol 44(4):663-670 Robinson WS 1994 Molecular events in the pathogenesis of hepadnavirus- associated hepatocellular carcinoma Annu Rev Med 45: 297-323 Robinson WS 1995 Hepatitis B virus and hepatitis D virus In: Mandell GL, Bennett JE, Dolin R, eds Principles and Practice of Infectious Diseases, 4th ed New York, Churchill Livingstone: 1406-1439 Romano N, Macino G 1992 Quelling: transient inactivation of gene expression in Neurospora crassa by transformation with homologous sequences Mol Microbiol 6(22):3343-3353 Ruvkun G, Wightman B, Ha I 2004 The 20 years it took to recognize the importance of tiny RNAs Cell 116 (2 Suppl): S93-96 Saksela K 2003 Human viruses under attack by small inhibitory RNA Trends Microbiol 11(8): 345-347 Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, Wolfsberg TG, Umayam L, Lee JC, Hughes CM, Shanmugam KS, Bhattacharjee A, Meyerson M, Collins FS 2004 Short 174 interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells Proc Natl Acad Sci U S A 101(7):1892-1897 Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M 2003 Specific inhibition of bcr-abl gene expression by small interfering RNA Blood 01(4):1566-1569 Schmid A, Schindelholz B, Zinn K 2002 Combinatorial RNAi: a method for evaluating the functions of gene families in Drosophila Trends Neurosci 25(2):71-74 Schwarz DS, Hutvagner G, Haley B, Zamore PD 2002 Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways Mol Cell 10(3): 537-548 Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD 2003 Asymmetry in the assembly of the RNAi enzyme complex Cell 115(2): 199-208 Sells MA, Zelent AZ, Shvartsman M, Acs G 1988 Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions J Virol 62(8): 2836-2844 Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN, Fesik SW 2003 Specificity of short interfering RNA determined through gene expression signatures Proc Natl Acad Sci U S A 100(11):6347-6352 Sherman M, Takayama Y 2004 Screening and treatment for hepatocellular carcinoma Gastroenterol Clin North Am 33(3):671-91, xi Sherman M 2005 Hepatocellular carcinoma: epidemiology, risk factors, and screening Semin Liver Dis.25(2):143-54 Shin D, Kim SI, Kim M, Park M 2006 Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene in mice.Virus Res 119(2):146-153 Shlomai A, Shaul Y 2003 Inhibition of hepatitis B virus expression and replication by RNA interference Hepatology 37(4):764-770 Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY 2006 miR-21-mediated tumor growth Oncogene advance online publication 30 October 2006 Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR 2003 Activation of the interferon system by short-interfering RNAs Nat Cell Biol 5(9):834-839 Stevenson M 2003 Dissecting HIV-1 through RNA interference Nat Rev Immunol 3(11): 851-858 175 Surabhi RM, Gaynor RB 2002 RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type replication J Virol 76(24):12963-12973 Tachibana K, Anzai N, Ueda C, Katayama T, Kirino T, Takahashi R, Yamasaki D, Ishimoto K, Tanaka T, Hamakubo T, Ueda Y, Arai H, Sakai J, Kodama T, Doi T 2006 Analysis of PPAR alpha function in human kidney cell line using siRNA Nucleic Acids Symp Ser (Oxf) (50):257-258 Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T 2004 Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival Cancer Res 64(11):3753–3756 Tam W, Dahlberg JE 2006 miR-155/BIC as an oncogenic microRNA Genes Chromosomes Cancer 45(2):211-212 Tan TM, Ting RC 1995 In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes Cancer Res 55(20):4599-4605 Tan TM, Zhou L, Houssais S, Seet BL, Jaenicke S, Peter F, Lim SG 2002 Intracellular inhibition of hepatitis B virus S gene expression by chimeric DNA-RNA phosphorothioate minimized ribozyme Antisense Nucleic Acid Drug Dev 12(4):257-264 Tang N, Huang AL, Zhang BQ, Yan G, He TC 2003 Potent and specific inhibition of hepatitis B virus antigen expression by RNA interference Zhonghua Yi Xue Za Zhi 83(15):1309-1312 Tang G 2005 siRNA and miRNA: an insight into RISCs Trends Biochem Sci 30(2): 106-114 Tanzer A, Stadler PF 2004 Molecular evolution of a microRNA cluster J Mol Biol 339(2):327-335 Terasawa K, Toyota M, Sagae S, Ogi K, Suzuki H, Sonoda T, Akino K, Maruyama R, Nishikawa N, Imai K, Shinomura Y, Saito T, Tokino T 2006 Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines Br J Cancer 94(6):914-921 Thomas D Schmittgen, Jinmai Jiang, Qian Liu and Liuqing Yang 2004 A high-throughput method to monitor the expression of microRNA precursors Nucleic Acids Research 32 (4): e43 Tomari Y, Matranga C, Haley B, Martinez N, Zamore PD 2004 A protein sensor for siRNA asymmetry Science 306(5700): 1377–1380 176 Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, Juni A, Ueda R, Saigo K 2004 Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference Nucleic Acids Res 32(3):936-948 Uprichard SL, Boyd B, Althage A, Chisari FV 2005 Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs Proc Natl Acad Sci U S A 102(3):773-778 Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM 2006 A microRNA expression signature of human solid tumors defines cancer gene targets Proc Natl Acad Sci U S A 103(7):2257-2261 Walder RY, Walder JA 1988 Role of RNase H in hybrid-arrested translation by antisense oligonucleotides Proc Natl Acad Sci U S A 85(14):5011-5015 Wang L, Prakash RK, Stein CA, Koehn RK, Ruffner DE 2003 Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo Antisense Nucleic Acid Drug Dev.13(3):169-189 Wang Q, Carmichael GG 2004 Effects of length and location on the cellular response to double-stranded RNA Microbiol Mol Biol Rev 68(3):432-452 Waterhouse PM, Wang MB, Lough T 2001 Gene silencing as an adaptive defence against viruses Nature 411(6839):834-42 Wightman B, Ha I, Ruvkun G 1993 Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C elegans Cell 75(5):855-862 Wilda M, Fuchs U, Wossmann W, Borkhardt A 2002 Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi) Oncogene 21(37):5716-5724 Will H, Grundhoff A 2006 Fighting viral hepatitis with small RNAs J Hepatol 44 (5):1009–1011 Wilson JA, Jayasena S, Khvorova A, Sabatinos S, Rodrigue-Gervais IG, Arya S, Sarangi F, Harris-Brandts M, Beaulieu S, Richardson CD 2003 RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells Proc Natl Acad Sci U S A 100(5):2783-2788 World Health Organization 1973 Viral Hepatitis Reposty of WHO Scientific Group WHO Technical Report Series 512 Geneva: WHO Worman HJ, Feng L, Mamiya N 1998 Molecular biology and the diagnosis and treatment of liver diseases World J Gastroenterol 4(3):185-191 177 Wu HL, Huang LR, Huang CC, Lai HL, Liu CJ, Huang YT, Hsu YW, Lu CY, Chen DS, Chen PJ 2005a RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant Gastroenterology 128(3):708-716 Wu K, Gong Y, Zhang X, Zhang Y, Mu Y, Liu F, Song D, Zhu Y, Wu J 2005e Inhibition of hepatitis B virus replication by recombinant small interfering RNAs.Acta Virol 49(4):235-241 Wu KL, Zhang X, Zhang J, Yang Y, Mu YX, Liu M, Lu L, Li Y, Zhu Y, Wu J 2005b Inhibition of Hepatitis B virus gene expression by single and dual small interfering RNA treatment Virus Res 112(1-2):100-107 Wu Y, Huang AL, Tang N, Zhang BQ, Lu NF 2005c RNA interference inhibits replication and expression of hepatitis B virus in mice Zhonghua Yi Xue Za Zhi 85(9):630-634 Wu Y, Huang AL, Tang N, Zhang BQ, Lu NF 2005d Specific anti-viral effects of RNA interference on replication and expression of hepatitis B virus in mice Chin Med J (Engl) 118(16):1351-1356 Xu P, Vernooy SY, Guo M, Hay BA 2003a The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism Curr Biol 13(9):790-795 Xu R, Cai K, Zheng D, Ma H, Xu S, Fan ST 2003b Molecular therapeutics of HBV Curr Gene Ther 3(4): 341-355 Xuan B, Qian Z, Hong J, Huang W 2006 EsiRNAs inhibit Hepatitis B virus replication in mice model more efficiently than synthesized siRNAs.Virus Res 118(1-2):150-155 Yan RQ, Su JJ, Huang DR, Gan YC, Yang C, Huang GH 1996, Human hepatitis B virus and hepatocellular carcinoma I Experimental infection of tree shrews with hepatitis B virus J Cancer Res Clin Oncol.122(5):283-288 Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC 2006 Unique microRNA molecular profiles in lung cancer diagnosis and prognosis Cancer Cell 9(3):189–198 Yang ZG, Chen Z, Xu N, Ni Q, Pan XC, Jin HY, Li MW 2004 Establish a screening system for selection of mRNA target sites for HBsAg to construct siRNA with shRNA Zhonghua Gan Zang Bing Za Zhi 12(9):515-518 Yao Z, Zhou Y, Feng X, Chen C, Guo J 1996 In vivo inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides in athymic nude mice J Viral Hepat 3(1):19-22 178 Ye JJ, Xu ZF, Chen Z, Cao J, Zheng S, Ding JY 2005 Inhibition of hepatitis B virus by combined siRNAs in vitro Shi Yan Sheng Wu Xue Bao 38(2):141-147 Yekta S, Shih IH, Bartel DP 2004 MicroRNA-directed cleavage of HOXB8 mRNA Science 304(5670): 594-596 Yguerabide J, Yguerabide E 1998a Light scattering submicroscopic particles as highly fluorescent analogs and their use as tracer labels in clinical and biological applications: theory Anal Biochem 262(2): 137-156 Yguerabide J, Yguerabide E 1998b Light scattering submicroscopic particles as highly fluorescent analogs and their use as tracer labels in clinical and biological applications: experimental characterization Anal Biochem 262(2): 157-176 Yi R, Qin Y, Macara IG, Cullen BR 2003 Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs Genes Dev 17(24): 3011–3016 Ying C, De Clercq E, Neyts J 2003 Selective inhibition of hepatitis B virus replication by RNA interference Biochem Biophys Res Commun 309(2):482-484 Ying RS, Fan XG, Zhu C, Li N, Zhang BX 2006 Inhibition of hepatitis B virus replication and expression by RNA interference in vivo Zhonghua Gan Zang Bing Za Zhi 14(1):15-18 Ying RS, Zhu C, Fan XG, Li N, Tian XF, Liu HB, Zhang BX 2007 Hepatitis B virus is inhibited by RNA interference in cell culture and in mice Antiviral Res 73(1):24-30 Zamore PD, Tuschl T, Sharp PA, Bartel DP 2000 RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals Cell 101(1):25-33 Zamore PD, Haley B 2005 Ribo-gnome: the big world of small RNAs Science 309(5740):1519-1524 Zhang H, Kolb FA, Brondani V, Billy E, Filipowicz W 2002 Human Dicer preferentially cleaves dsRNAs at their termini without a requirement for ATP EMBO J 21(21): 5875–5885 Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR, Yao G, Medina A, O'brien-Jenkins A, Katsaros D, Hatzigeorgiou A, Gimotty PA, Weber BL, Coukos G 2006 microRNAs exhibit high frequency genomic alterations in human cancer Proc Natl Acad Sci U S A 103(24):9136-9141 Zhang XN, Xiong W, Wang JD, Hu YW, Xiang L, Yuan ZH.2004 siRNA-mediated inhibition of HBV replication and expression.World J Gastroenterol 10(20):2967-2971 179 Zhao ZF, Yang H, Han DW, Zhao LF, Zhang GY, Zhang Y, Liu MS 2006 Inhibition of hepatitis B virus expression and replication by RNA interference in HepG2.2.15.World J Gastroenterol 12(37):6046-6049 Zhou XM, Lin JS, Shi Y, Tian DA, Huang HJ, Zhou HJ, Jin YX 2005 Establishment of a screening system for selection of siRNA target sites directed against hepatitis B virus surface gene Acta Biochim Biophys Sin (Shanghai) 37(5):310-316 Zhu C, Fan XG, Li N, Ying RS 2004 Inhibition of hepatitis B virus replication by RNA interference in vitro Zhonghua Gan Zang Bing Za Zhi 12(9):522-525 Zhu C, Fan XG, Li N, Ying RS, Tian XF 2005 Inhibition of hepatitis B virus replication and expression by RNA interference in vitro Zhonghua Yi Xue Za Zhi 85(35):2503-2506 180 SUPPLEMENTARY MATERIAL Table S1 Clinical characteristics of 56 patients NO Diagnosis Aetiology Cirrhosis TNM Age Sex Race 23 Poorly differentiated HCC HBV + T3 N0 M0 stage IIIA 49 M Chinese 27 Moderately differentiated HCC HBV + T3 N0 M1 stage IVB 57 M Chinese 47 Moderately differentiated HCC HBV + T3 N0 M0 stage IIIA 47 M Chinese 48 Poorly differentiated HCC HBV - T4 N0 M0 stage IVA 54 F Indonesian 51 Moderately differentiated HCC HCV + T2 N0 M0 stage II 59 M Chinese 52 Moderately differentiated HCC HBV + T3 N0 M0 stage IIIA 55 M Chinese 57 Moderately differentiated HCC HBV - T3 N0 M0 stage IIIA 46 M Chinese 67 Moderately differentiated HCC HBV + T3 N0 M0 stage IIIA 59 F Chinese 77 Well differentiated HCC Cryptogenic + T3 N0 M0 stage IIIA 67 M Indonesian 78 Well differentiated HCC HBV + T3 N0 M0 stage IIIA 56 M Chinese 81 Poorly differentiated HCC Cryptogenic - T3 N0 M0 stage IIIA 71 F Chinese 83 Poorly differentiated HCC HBV + T4 N0 M0 stage IVA 52 M Chinese 96 Moderately differentiated HCC HBV - T3 N1 M0 stage IIIB 71 M Chinese 104 Poorly differentiated HCC HBV + T4 N0 M0 stage IVA 44 M Chinese 108 Moderately differentiated HCC HBV - NIL 65 M Chinese 111 Poorly differentiated HCC HBV - T4 N0 M0 stage IVA 39 M Chinese 117 Poorly differentiated HCC Cryptogenic - T3 N0 M0 stage IIIA 54 M Indian 118 Moderately differentiated HCC HBV + T4 N0 M0 stage IVA 47 M Myanmar 120 Poorly differentiated HCC HBV + T3 N0 M0 stage IIIA 66 M Indian 121 Moderately differentiated HCC HBV + T3 N0 M0 stage IIIA 63 M Chinese 123 Well differentiated clear cell HCC Cryptogenic - 56 M Chinese 125 Moderately differentiated HCC Cryptogenic - T2 N0 M0 stage IIIA 61 M Chinese 126 Poorly differentiated HCC HBV + T3 N0 M0 stage IIIA 53 M Chinese 127 Moderately differentiated HCC HBV - T4 N0 M0 stage IVA 52 M Chinese 129 Moderately differentiated HCC Cryptogenic + T3 N0 M0 stage IIIA 76 F Chinese 131 Moderately differentiated HCC HBV + T3 N0 M0 stage IIIA 32 M Chinese 132 Well differentiated clear cell HCC HCV + 59 M Indian 135 Poorly differentiated HCC Cryptogenic - 62 M Pakistani T2 N0 M0 stage II T3 N0 M0 stage IIIA T4 N0 M0 stage IVA 181 136 Moderately differentiated HCC HBV + T2 N0 M0 stage II 71 M Chinese 137 Moderately differentiated HCC HBV + T4 N0 M0 stage IVA 62 M Myanmar 148 Poorly differentiated HCC HBV + T3 N0 M0 stage IIIA 68 M Chinese 149 Moderately differentiated HCC HBV + T3 N0 M0 stage IIIA 65 M Indonesian 150 Poorly differentiated HCC HBV - T3 N0 M0 stage IIIA 44 M Chinese 151 Moderately differentiated HCC HBV + T4 N0 M0 stage IVA 82 F Chinese 153 Moderately differentiated HCC HBV + T3 N0 M0 stage IIIA 60 M Indonesian 155 Poorly differentiated HCC HBV + T4 N0 M0 stage IVA 63 M Chinese 156 Moderately differentiated HCC HBV - T3 N0 M0 stage IIIA 53 M Chinese 158 Moderately differentiated HCC Cryptogenic + T3 N0 M0 stage IIIA 76 F Malay 160 Poorly differentiated HCC HBV + T3 N0 M0 stage IIIA 56 M Chinese 169 Poorly differentiated HCC HCV + T4 N0 M0 stage IVA 67 M Malay 174 Well differentiated cell HCC Cryptogenic - T2 N0 M0 stage II 68 F Indonesian 186 Moderately differentiated HCC Cryptogenic + NIL 37 F Chinese 187 Poorly differentiated HCC HBV + T3N0M0 61 M Chinese 192 Moderately differentiated HCC Cholangio - NIL 71 F Chinese 193 Moderately differentiated HCC HBV - T4N0M0 38 M Chinese 195 Poorly differentiated HCC HCV + T2 N0 M0 stage II 65 M Indonesian 196 Moderately differentiated HCC HBV + T3N0M0 40 M Chinese 197 Moderately differentiated HCC Cryptogenic - T3N0M0 72 M Indonisian 204 Moderately differentiated HCC Cryptogenic - T2NXMX 74 M Chinese 211 Poorly differentiated HCC Cryptogenic - T3NXMX 57 F Malaysian 222 NIL HBV - NIL NIL NIL NIL 233 Poorly differentiated HCC HBV - T1NXMX 53 M Chinese 240 Moderately differentiated HCC HBV - T2NXMX 70 M Chinese 246 well differentiated HCC HBV - T2NXMX 54 M Chinese 247 well differentiated HCC HBV - T3N0MX 44 F Chinese 248 NIL HBV - NIL NIL NIL NIL 182 ... proteins; TP: terminal protein During HBV infection in human, virus particles are present in a large quantity in patient blood Both infectious and non-infectious particles can be found in the... diagnosis and treatment of HCC 1.2 HBV-the Virus and the Disease HBV is a small enveloped DNA virus which can cause acute and chronic infection of the liver (Robinson, 1994) HBV infection remains a... antigen HBsAg Hepatitis B surface antigen HBV Hepatitis B virus HCC Hepatocellular carcinoma HCV Hepatitis C virus HIV Human immunodeficiency virus IFN Interferon IFN-α Interferon alpha IRES Internal